Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4Observational 1

Sponsor

Conditions

Pain 5Neoplasms 5Cancer Pain 2Neuralgia 1Chronic Pain 1Breast Neoplasms 1Agnosia 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Neoplasms × Tapentadol × Clear all
NCT00472303 2019-11-04

A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine

Grünenthal GmbH

Phase 3 Completed
622 enrolled 31 charts

Cancer Pain, Neoplasms, Pain

NCT01264887 2019-11-04

Tapentadol in Chronic Malignant Tumour Related Pain

Grünenthal GmbH

Phase 3 Terminated
31 enrolled 19 charts

Agnosia, Neoplasms, Pain, Chronic Pain

NCT00505414 2019-11-01

A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine

Grünenthal GmbH

Phase 3 Terminated
136 enrolled 9 charts

Neoplasms, Pain

NCT01946555 2016-04-14

RER

Mario Negri Institute for Pharmacological Research

Completed
150 enrolled

Cancer Pain, Neoplasms, Neuralgia

NCT00805142 2013-07-29

Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants

Janssen Pharmaceutical K.K.

Phase 2 Completed
78 enrolled 16 charts

Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡